We are live on ! Find out more
IMI

Intermolecular, Inc.
IMI

Delisted

IMI was delisted on the 19th of September, 2019.

24 hedge funds and large institutions have $25.3M invested in Intermolecular, Inc. in 2017 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 2

34% more capital invested

Capital invested by funds: $19M → $25.3M (+$6.36M)

20% more funds holding

Funds holding: 2024 (+4)

33% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 6

Holders
24
Holders Change
+4
Holders Change %
+20%
% of All Funds
0.54%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
6
Increased
4
Reduced
6
Closed
2
Calls
Puts
Net Calls
Net Calls Change

IMI Hedge Fund Activity: Q4 2017 in Review

24 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Intermolecular, Inc. (IMI) for Q4 2017, worth a combined $25.3M — up 34% from $19M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new IMI positions and 2 closed out — a net gain of 4 holders — while 4 added to existing stakes and 6 trimmed.

The largest buyer was Essex Investment Management, opening a new position worth an estimated $203K. The largest seller was T. Rowe Price Associates, cutting an estimated $580K.

  • 24 institutional investors held Intermolecular, Inc. (IMI) as of Q4 2017, up from 20 in Q3 2017.
  • Funds reported $25.3M of Intermolecular, Inc. stock for Q4 2017, up 34% quarter-over-quarter.
  • 6 funds opened new Intermolecular, Inc. positions in Q4 2017 and 2 closed out, a net change of +4 holders.
  • The largest Intermolecular, Inc. buyer in Q4 2017 was Essex Investment Management, an estimated $203K added.
  • The largest Intermolecular, Inc. seller in Q4 2017 was T. Rowe Price Associates, an estimated $580K sold.

Based on aggregated 13F filings for Q4 2017.